MediGene keeps cancer-killing viruses patent

By Elaine Rigoli

Tampa, Fla., June 8 - MediGene AG said it has successfully defended a patent on herpes simplex viruses (HSV) before the Boards of Appeal at the European Patent Office.

The patent as maintained protects a production method for herpes simplex virus-1 vaccines, including specific oncolytic herpes simplex viruses (cancer-killing HSV) developed by MediGene, according to a news release.

The University College of London and the University Court of the University of Glasgow had opposed the patent.

This protection will not expire until September 2011. In case of marketing authorization prior to that date, the protection may be extended by up to five more years.

German-American biotech company MediGene has U.S. headquarters in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.